United States: A Closer Look At CMS' Drug Price Disclosure Proposal

On Oct. 15, 2018, the Centers for Medicare & Medicaid Services released a proposed rule regarding the disclosure of pricing information in direct-to-consumer television ads for prescription drugs and biologics reimbursable by Medicare and Medicaid. The proposed rule would amend relevant Medicare and Medicaid regulations to require DTC television ads (including broadcast, cable, streaming and satellite communication) of prescription drug and biological products for which reimbursement is available through or under Medicare and Medicaid to include the list price, defined as the wholesale acquisition cost, or WAC, of that drug or biological product. More specifically, the proposed rule would:

  • Apply to any prescription drug or biological product with a list price of at least $35/month for a 30-day supply or typical course of treatment that is distributed in the U.S. and for which payment is available under Medicare or Medicaid;
  • Require television ads for such covered pharmaceuticals to contain a textual statement indicating the WAC for a typical 30-day regimen or a typical course of treatment, whichever is most appropriate, as determined on the first day of the quarter during which the advertisement is being aired or broadcast as follows:
  • "The list price for a [30-day supply of] [typical course of treatment with] [name of prescription drug or biological product] is [insert list price]. If you have health insurance that covers drugs, your cost may be different."
  • Require that the disclosure use the most current list price as of the date of publication/broadcast and use the list price for the "course of treatment" associated with the primary indication advertised if the price is related to a "typical course of treatment" that depends on the drug's prescribed indication;
  • Require that the disclosure appear at the end of the ad in a legible manner against a contrasting background for sufficient duration and in a size and style of font that allows the information to be read easily; and
  • Allow the U.S. Department of Health & Human Services to maintain a public list of drugs and biological products advertised in violation of the rule.

Notably, although the HHS secretary would maintain a public list of drugs and biological products identified to be in violation of the rule, the proposed rule would not provide any HHS-specific enforcement mechanism for noncompliance. CMS "anticipate[s] that the primary enforcement mechanism will be the threat of private actions under the Lanham Act" for unfair competition in the form of false or misleading advertising. CMS asserts that "the Lanham Act ... is the most appropriate mechanism for enforcing against deceptive trade practices."

Among other things, CMS seeks comments regarding the price disclosure statement's content, whether the regulation should apply to other forms of media, whether compliance with the rule should be a condition to payment from federal health programs, whether CMS's proposed compliance regime and reliance on private civil actions under the Lanham Act is appropriate and effective, whether WAC best reflects list price, whether a 30-day supply and typical course of treatment are appropriate metrics, and how list price disclosure may influence patient interactions with prescribers, the selection of drug products and perceived drug efficacy. Comments are due by Dec. 17, 2018.

Scope of CMS Authority to Issue the Rule

Despite the absence of specific authority to issue regulations related to drug pricing transparency, CMS is issuing the proposed rule pursuant to sections of the Social Security Act that provide HHS with the authority to issue regulations "for the efficient administration of functions" under the act and "as may be necessary to carry out the administration of the insurance programs" under Medicare.

Parties commenting on the proposed rule may wish to address whether communications between manufacturers and prospective patients, which are relatively remote from CMS's insurance programs, are within the scope of CMS's rule-making authority under the cited provisions. It would appear that HHS believed that tying the proposed rule to Medicare/Medicaid, government programs in which companies choose to participate and seek reimbursement, would provide HHS with a stronger basis for asserting authority to issue this rule than trying to tie it to the authority of the U.S. Food and Drug Administration to regulate drug advertising and promotion under the Federal Food Drug and Cosmetic Act. While the FDCA provides the FDA with the authority to regulate certain aspects of prescription drug advertising and promotion, the FDA arguably lacks the statutory authority to require such disclosure absent a finding that the lack of pricing information constitutes "misbranding" or is otherwise noncompliant with FDCA requirements in relation to disclosure of safety-related information.

First Amendment Considerations

Apparently anticipating that the proposed rule will elicit objections under the First Amendment, CMS takes the position that requiring the disclosure of pricing information in DTC television advertisements is consistent with First Amendment jurisprudence. Specifically, CMS asserts that regulations concerning disclosures of "factual, noncontroversial information" in commercial speech may be subject to more deferential First Amendment scrutiny. Relying on, among other precedents, the U.S. Supreme Court's 1985 decision in Zauderer v. Office of Disciplinary Counsel, CMS states that courts have upheld required disclosures of factual information in commercial speech where the disclosure requirement reasonably relates to a government interest and is not unjustified or unduly burdensome such that it would chill protected speech.

In considering the strength of the government's First Amendment arguments and potential challenges, a key consideration is the appropriate standard of review. The level of scrutiny that is ultimately applied would be a major factor in determining the likelihood of success of any challenge to the CMS proposed rule. Depending on the nature of the speech regulation and context, various standards of review may apply, including in order of greater to lesser scrutiny: strict or heightened scrutiny, the traditional commercial speech test (the Central Hudson test) and the Zauderer test.

One important difference between the standards is how strong the government's interest must be in order to justify the regulation. For example, if analyzed under heightened scrutiny or the Central Hudson test, a challenger could assert that the government has no substantial, much less compelling, interest in deterring the usage and reimbursement of prescriptions for FDA-approved products that licensed health care providers determine are medically appropriate to prescribe. The strength of any such asserted interest would appear even weaker in light of the fact that the pricing information required to be provided to consumers bears little to no relationship to the cost the consumer would actually experience. One could even argue that CMS is deterring FDA-approved uses through the compelled dissemination of information that is false or misleading. Notably, while to our knowledge no regulator or plaintiff has ever contended that the omission of WAC from advertising rendered that advertising false or misleading, in several instances claims have been asserted that a "list price" was, at least in context, misleading. If the regulation is required to satisfy a more demanding level of governmental interest, these weaknesses could be determinative.

Another critical difference between the standards of review is the required degree of fit between the CMS proposed rule and the objective it is attempting to achieve. If, for example, Zauderer applies, the government must only prove that its method is "reasonably related" to its interest; if Central Hudson applies, the regulation must "directly advance" the interest and not be "more extensive than necessary." The case law is clear that the Central Hudson standard is significantly stricter than the Zauderer standard of review (which is akin to rational basis review). If Central Hudson scrutiny — or an even more heightened level of scrutiny — were applied, it would be easier to point to alternative options (e.g., making pricing information available to consumers by providing website links) and suggest that the government was not reasonably tailoring its regulation to meet its objectives.

Lanham Act Considerations

CMS has indicated that it expects the primary enforcement mechanism for the proposed rule will be the threat of private Lanham Act challenges. While the Lanham Act can act as a private enforcement mechanism, complementing federal labeling and advertising requirements, enforcement of this proposed rule may be significantly limited due to the standing requirements and elements of a Lanham Act claim.

With regard to standing, consumers do not have standing under the Lanham Act, and challenges would need to be brought by competitors or others who can demonstrate commercial harm caused by the defendant's advertising.1 Competitors may also lack standing in many instances if they are not harmed by a particular advertisement's omission of list price.

Another key limitation of the Lanham Act is that, in general, omissions (e.g., omission of list price) can be actionable under the Lanham Act only to the extent the advertising contains affirmative statements that, while literally true, may be misleading to an appreciable percentage of the audience in the absence of the information that has been omitted.

State Law Preemption

With respect to preemption of state laws, CMS's proposed regulations state that "[n]o State or political subdivision of any State may establish or continue in effect any requirement that depends in whole or in part on any pricing statement required by this subpart." In the preamble, CMS further explains that its proposed rule is intended to preempt state-law-based claims to enforce the new disclosure requirement as follows: "consistent with our not including any HHS-specific enforcement mechanism in this proposal, we are proposing ... that this rule preempt any state-law-based claim which depends in whole or in part on any pricing statement required by this rule." CMS implies that, in contrast with sophisticated competitors bringing suit under the Lanham Act, allowing state-law-based claims, which can often be brought by consumers, would "increase transactional costs in defending meritless litigation" and thus undermine its "broader initiative to reduce the price to consumers of prescription drugs and biological products."

The precise scope of preemption by the CMS rule is unclear. Some state-law-based claims, such as a claim brought under California's well-known Unfair Competition Law,2 would potentially provide a more effective avenue for challenging a competitor's omission of pricing information than the Lanham Act.3 Notably, however, we are unaware of such statutes ever having been invoked to challenge a pharmaceutical or biologic manufacturer's omission of list price from DTC advertising. If such a challenge were brought now, it would strongly appear that such a claim would be the kind of attempt to enforce the CMS rule that CMS seeks to preclude. The effect of the rule on existing (or future) state pricing transparency legislation is not specified, an issue on which clients may want to seek clarity.

Other Considerations

There are a number of questions regarding the impact of the proposed rule that will require further consideration in addition to those highlighted above. These additional considerations include, for example:

  • The impact of failure to provide pricing information on the ability of companies to certify to compliance with law as required by a corporate integrity agreement or in other similar contexts;
  • Potential False Claims Act implications of noncompliance;
  • Potential Medicare/Medicaid exclusion implications of noncompliance;
  • Interaction of the proposed rule with PhRMA's voluntary disclosure program announced Oct. 15, 2018, under which member companies will (by April 2019) voluntarily include information in DTC television ads directing consumers to information about drug costs, including list price, estimated out-of-pocket costs and availability of financial assistance; and
  • FDA considerations, including (1) whether television ads would need to be resubmitted to FDA for review every time the WAC is revised and (2) the extent to which additional voluntary pricing information could be included in an advertisement without being considered misleading (e.g., inclusion of competitor pricing information or information on estimated out-of-pocket costs).

Footnotes

1 See Lexmark Int'l, Inc. v. Static Control Components, Inc., 134 S. Ct. 1377, 1395 (2014).

2 Bus. & Prof. Code §17200

3 See also, e.g., Stutman v. Chem. Bank , 731 N.E.2d 608, 611-612 (N.Y. 2000) (stating an omission can be a deceptive practice under NY General Business Law § 349); Connick v. Suzuki Motor Co., Ltd., 675 N.E.2d 584, 595 (Ill. 1996) ("An omission or concealment of material fact in the conduct of trade or commerce constitutes consumer fraud [under the Illinois Consumer Fraud Act].").

This article by partners Kellie CombsDouglas Hallward-DriemeierPeter BrodyTom Bulleit and Albert Cacozza was published by Law360 on October 24, 2018.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions